Compass Therapeutics (NASDAQ:CMPX) Stock Price Down 7.6% – Here’s Why

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) dropped 7.6% during trading on Tuesday . The stock traded as low as $3.60 and last traded at $3.61. Approximately 1,262,924 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 2,397,288 shares. The stock had previously closed at $3.90.

Analyst Upgrades and Downgrades

CMPX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. D. Boral Capital reissued a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs lowered shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Jefferies Financial Group lifted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $11.17.

Compass Therapeutics Trading Down 6.4 %

The stock has a market cap of $502.20 million, a P/E ratio of -9.86 and a beta of 1.17. The firm’s 50-day simple moving average is $2.12 and its 200 day simple moving average is $1.74.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, analysts anticipate that Compass Therapeutics, Inc. will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC lifted its stake in Compass Therapeutics by 218.7% during the fourth quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after purchasing an additional 35,632 shares during the last quarter. Sequoia Financial Advisors LLC acquired a new position in Compass Therapeutics in the 4th quarter valued at approximately $45,000. Independent Advisor Alliance acquired a new position in Compass Therapeutics in the 4th quarter valued at approximately $26,000. Bank of New York Mellon Corp increased its stake in shares of Compass Therapeutics by 2.6% during the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock worth $345,000 after purchasing an additional 6,041 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in shares of Compass Therapeutics by 3.1% during the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock worth $187,000 after purchasing an additional 3,822 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.